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ABSTRACT OF THE DISSERTATION
Effects of Cigarette Smoking on Neurocognitive Performance in
Dementia Patients
by
Christina Mannino
Doctor of Philosophy, Graduate Program in Biochemistry
Loma Linda University, September 2014
Dr. Holly Morrell, Chairperson

Dementia has become a serious problem worldwide due to the rapidly increasing
incidence rate and the lack of effective treatments that cure or slow disease progression,
and thus. prevention is crucial. Some studies suggests that cigarette smoking may
increase the risk of developing dementia, but others suggest that smoking may have a
neuroprotective effect. To clarify our understanding of the relationship between cigarette
smoking and dementia, this study examined the effects of smoking on multiple cognitive
domains via secondary data analysis of a sample consisting of 54% female subjects with
an average age of 58±13 years. Measures of executive function, verbal memory,
attention, and processing speed were administered to two groups of dementia patients,
never smokers and current/former smokers. Hierarchical linear regression analysis was
used to test smoking status as a predictor of functioning in each of these four cognitive
domains after controlling for potentially confounding factors such as cardiovascular
disease, type 2 diabetes, depression, anxiety, and substance use. No relationship was
found between smoking, any of the covariates, and cognitive performance in any domain.
Future research should utilize a prospective design and administer neuropsychological
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batteries to participants in early or middle adulthood who have not been yet diagnosed
with dementia.
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CHAPTER ONE
INTRODUCTION

Dementia has become a serious worldwide problem, as it is the leading cause of
functional limitation among older adults (APA, 2012). In developed countries, the
prevalence of dementia ranges from 5% to 10% in individuals over age 65 and affects as
many as 50% of the population age 85 and older (Rincon & Wright, 2013). In the United
States alone, one in three adults will develop dementia or suffer a stroke in their lifetime.
Even more startling is the fact that the prevalence of Alzheimer’s disease (AD), an illness
characterized by plaques and tangles in the brain, early onset memory impairment,
deficits in naming and visuoconstruction abilities, and social withdrawal (Schoenberg &
Duff, 2011), doubles every 4.3 years. Additionally, AD is currently the sixth leading
cause of death in the U.S. and the fifth leading cause in people over age 65. (Alzheimer’s
Association, 2012). Perhaps the most disheartening fact concerning dementia is that
among the top 10 leading causes of death in the U.S., AD is the only one without a cure,
a course of prevention, or even a way to slow its progression (Alzheimer’s Association,
2012). Moreover, the current Alzheimer’s disease literature posits that the complex
pathophysiological process of AD begins years, and perhaps even a decade or more,
before the symptoms manifest; therefore, prevention is crucial (Sperling, Karlawish, &
Johnson, 2013).
Similarly, the prevalence of vascular dementia (VaD), a disease typified by early
deficits in attention, executive function, processing speed, and visuoconstruction skills
(Schoenberg & Duff, 2011), doubles every 5.3 years (Rincon & Wright, 2013).
Unfortunately, there is a lack of literature on the rate of increase in prevalence of
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dementia with Lewy bodies (DLB) or frontotemporal dementia (FTD). Estimates of the
prevalence of DLB, an illness notable for abnormal protein aggregates known as Lewy
Bodies, motor impairment, fluctuating mental clarity, and vivid visual hallucinations of
people or animals (Schoenberg & Duff, 2011), are as high as 5% in the general
population and 30.5% of all dementia cases, rendering DLB the second most common
type of dementia after AD (Zaccia, McCracken, & Brayne, 2005). Epidemiological data
also suggest that FTD, a disease characterized by early onset of executive dysfunction
and personality changes and impairments in confrontation naming and verbal fluency
(Schoenberg & Duff, 2011), has an incidence and prevalence similar to AD as a common
cause of early onset dementia in individuals younger than 65 years of age (Rabinovici &
Miller, 2010). These statistics, in conjunction with the prediction that by the year 2030
the portion of the U.S. population over age 65 will double, suggest that health care costs
associated with dementia will increase substantially (Hurd et al., 2013). Given that there
are no cures for dementia in the foreseeable future, prevention is the key, but it is not
possible unless the risk factors of dementia are identified.
A number of factors thought to increase the risk of dementia have been described
in the literature. The risk factors most commonly discussed are age, family history,
hypertension, high cholesterol, diabetes, depression, cigarette smoking, and alcohol use
(Mayo Clinic Staff, 2014). While age and family history cannot be changed, the other
factors can be avoided, prevented, or controlled by lifestyle changes, such as
improvements in diet and exercise, quitting smoking, and/or adhering to treatment with
medication. In particular, cigarettes are probably the most significant source of chemical
toxins in humans. They are the leading preventable cause of death in the United States
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(U.S. Department of Health and Human Services, 2014) and have been forecasted by the
World Health Organization as being the cause of death for approximately nine million
people per year globally by the year 2030 (Swan & Lessov-Schlaggar, 2007). Smoking is
associated with an increased incidence of cardiovascular disease including
cerebrovascular disease, coronary heart disease, and vascular diseases.
Given the association between smoking and cardiovascular disease, and the link
between cardiovascular disease and increased risk for dementia (Peters, 2012), it is not
surprising that a number of studies have suggested a link between cigarette smoking and
AD and VaD (Peters et al., 2008; Rincon & Wright, 2013; Rusanen et al., 2011; Swan &
Lessov-Schlaggar, 2007). In contrast, a study examining the potential relationship
between cigarette smoking and the risk of neuropathologic changes of Lewy-related
pathology (LRP) in the brain (Tsuang et al., 2009) found that smoking was associated
with significantly reduced relative risk for LRP, which is characteristic of DLB and
sometimes found in cases of AD. However, this is only one study, and more
investigations into the relationship between smoking and DLB are necessary to determine
if tobacco reduces the risk of DLB. In the case of frontotemporal dementia, very little is
known about the risk factors associated with this dementia as compared with AD and
VaD (Kalkonde et al., 2012). Therefore, we need a better understanding of cigarette
smoking as a potential risk factor for the various types of dementia.
Cardiovascular damage is not the only way in which smoking may be connected
to the development of a neurodegenerative disorder. Many of the more than 4,700
constituents of cigarette smoke are associated with brain toxicity, such as hydrogen
cyanide, arsenic, and vinyl chloride, a chemical thought to be connected with brain
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cancer (Fowles & Dybing, 2003). Especially problematic are the heavy metals present in
tobacco smoke, such as lead and cadmium, which in recent epidemiological studies have
been shown to be a risk factor for AD pathology (i.e., plaques and tangles) via an
increase in oxidative stress (Bernhard, Rossmann, & Wick, 2005; Liu et al., 2006).
Lifetime exposure to lead is cross-sectionally associated with cognitive decline in
executive functioning, verbal memory and learning, visual learning, processing speed,
language, and visual construction, as well as decreases in brain volume and increases in
the number of white matter lesions (Shih et al., 2006). Cigarettes are also a significant
source of oxidative stress through direct exposure, the inflammatory immune response
pathway, and glutamate neurotoxicity (Swan & Lessov-Schlaggar, 2007). Oxidative
stress refers to cell injury mediated by reactive oxygen and nitrogen species. Oxidative
stress is currently thought to play an important part in the neurodegenerative process of
AD as the resulting damage has been reported extensively in AD patients (Practicò, 2008,
Wang et al., 2013). The reactive species, unavoidable byproducts of normal metabolic
reactions, are generally chemically unstable and highly reactive. When an excess of these
reactive species are present in a biological system they are capable of oxidizing DNA,
RNA, protein, and lipids, resulting in cell damage (Wang et al., 2013).
Given all of the known toxic effects of cigarette smoke on the human body, the
relationship between smoking and cognitive decline/dementia would seem to be
intuitively obvious, but that is not the case. The literature in this area is mixed, with some
studies suggesting an increased risk for dementia and others suggesting that tobacco
actually protects against dementia. For example, a number of prospective studies have
found a significant association between increased risk of dementia and current cigarette
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smoking (Hirayama et al., 1992; Juan et al., 2004; Launer et al., 1999; Merchant et al.,
1999; Ott et al., 1998; Reitz et al., 2005). Additional prospective studies have also
demonstrated a significant link between smoking and increased risk of cognitive decline
that does not meet the DSM-IV criteria for dementia (Aggarwal et al., 2006; Collins et
al., 2009; Galanis et al., 1997; Nooyens et al., 2008; Ott et al., 2004; Reitz et al., 2005;
Sabia et al., 2008). Finally, another prospective study conducted on women participants
found that avoiding cigarette smoking significantly predicted maintenance of cognitive
function (Barnes et al., 2007).
While the majority of prospective studies have demonstrated a positive
association between smoking and dementia, a prospective study conducted in Taiwan
showed that cigarette smoking decreased the risk of cognitive decline (Wang et al.,
2010). The results of this study may be due to participant attrition, which was attributed
to death or loss to follow-up. The literature suggests that smoking-related mortality may
mask the association between Alzheimer’s disease and smoking (Chang, Zhao, Lee, &
Ganguli, 2012; Kryscio et al., 2013). Two additional prospective studies have suggested
that there is no link between smoking and dementia. A prospective analysis from the
Canadian Study of Health and Aging found that smoking was not related to the risk of
AD (Lindsay et al., 2002). Another prospective study of wine and tobacco consumption
suggested that smoking is associated with a decreased risk of decline in attention and
visuospatial functioning (Leibovici et al., 1999).
In contrast, a number of case-control studies conducted in the 1980s and early
1990s showed that smoking might protect individuals from the onset of AD. Lee (1994)
performed a meta-analysis on 13 of these case-control studies and found that there was a
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40% reduction in risk of AD among cigarette smokers. Several articles have posited that
the seemingly counterintuitive results may be due to biases in study design (Kukull,
2001; Anstey et al., 2007; Cataldo, Prochaska, & Glantz, 2010). Case-control studies can
be biased if the way in which cases and controls are identified and enrolled is associated
with smoking history. These types of studies can also be biased if smoking history is
obtained differently for cases and controls. Recall bias is also a well-known problem of
case-control studies. For the smoking case-control studies, recall bias results from
discrepancies in the reporting of smoking status by case and control participants (Kukull,
2001). Unsurprisingly, a meta-analysis of the case-control studies conducted by Lee
(1994), who was a paid statistical consultant for the tobacco industry (Cataldo,
Prochaska, & Glantz, 2010), observed the same trend as the original case-control studies.
Regardless of Lee’s admonition that “prospective studies are often more scientifically
valid than case-control studies,” the tobacco industry continued to fund case-control
studies. It should also be noted that a meta-analysis performed by Cataldo, Prochaska,
and Glantz (2010) found that even after controlling for study design, tobacco industry
affiliation was associated with findings of decreased risk of AD in smokers. Given the
conflicting current literature and the urgent need to ascertain dementia risk factors, it is
important to determine the nature of the relationship between smoking and dementia as
well as the cognitive domains that are affected by cigarette smoking.
Studies examining the level of risk of cognitive impairment or decline among
former smokers compared to never smokers have also produced equivocal results. One
reason for these mixed results is that few of the studies investigating the relationship
between smoking and risk of dementia or cognitive decline differentiated between long-
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term ex-smokers and recent ex-smokers (Sabia et al., 2012). A number of studies have
found that ex-smokers either have similar declines in cognition or slower declines than
never smokers due to the ambiguous definition of former smokers (Anstey et al., 2007;
Peters et al., 2008; Sabia et al., 2012). The studies that differentiated between the two
levels of ex-smokers found that long-term former smokers exhibited similar risk of
cognitive impairment as never smokers (Galanis et al., 1997; Sabia et al., 2012). Almeida
et al. (2011) found that the cognitive scores of chronic smokers (i.e., smoked a minimum
of five cigarettes per day for a continuous period of 12 months or more throughout their
lifetime) who quit smoking for a minimum of 18 months were comparable to those of
never smokers. In contrast, it is possible that long-term former smokers’ risk may be
reduced to the level of never smokers’ risk, although more research is needed to clarify
this. The tobacco literature indicates that many of the body’s systems damaged by
cigarette smoking return to the condition of a nonsmoker when the smoker has abstained
from smoking for a long enough duration (e.g., risk of coronary heart disease is the same
as for nonsmokers after 15 years of abstinence; Abrams et al., 2003). Given that the heart
and lungs heal, and a number of the studies of the relationship between smoking and
cognition found no differences between the cognition of never smokers and long-term exsmokers (Galanis et al., 1997; Sabia et al., 2012), it is possible that the brain heals as well
or that a reduction in cardiovascular risk translates into a reduction in the risk for
dementia.
The variability in the procedures utilized for testing cognition is another potential
source of inconsistent outcomes in studies on the link between smoking and dementia. A
number of studies (Juan et al., 2004; Ott et al., 2004; Wang et al., 2010) measured
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cognitive decline using only the Mini-Mental State Examination (MMSE; Folstein,
Folstein, & McHugh, 1975) or the Short Portable Mental Status Questionnaire (SPMSQ;
Pfeiffer, 1975). The MMSE and SPMSQ both have good specificity, but limited
sensitivity (Lezak, 2004). The MMSE is most effective at distinguishing participants with
moderate to severe cognitive deficits from control participants, but less effective at
distinguishing control participants from those with mild deficits. Unlike many
neuropsychological tests, these screening measures use a cutoff score rather than
comparing each participant’s score with the scores of other individuals the same age. In
the case of the MMSE, a cut-off score of 24 is applied without accounting for potential
differences due to the participant’s age or level of education, which are factors known to
affect measures of cognition. Furthermore, using a cut-off of 24 may lead to incorrectly
classifying a participant with subtle or focal cognitive deficits. The lack of sensitivity of
these measures and the use of cutoff scores is problematic when studying the possible
relationship between smoking and dementia because of the risk of type II errors.
Screening measures such as the MMSE are more likely to fail to detect dementia,
especially early in the disease process, than a measure with good sensitivity that is
normed by age and education level.
As with most brief screening instruments, the MMSE and SPMSQ are affected by
age (Lezak, 2004). For example, in a sample of community-dwelling participants, the
average number of correct items on the SPMSQ dropped from 7.8 among participants
ages 65 to 69 to 6.05 among participants ages 85 to 89 (Scherr et al., 1988). Given that
cognition declines with age even in healthy individuals, the scores for ages 70 to 97 are
likely to be lower than those for ages 18 to 69 (Soubelet & Salthouse, 2011) on a measure
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such as the MMSE, regardless of health and lifestyle factors. These age effects may make
it difficult to detect differences in cognitive functioning due to smoking because a study
with an age range of 55 to 70 is likely to produce different results compared to a study
with an age range of 65 to 80, regardless of whether participants are current smokers.
Another problem with studies using single, gross measures of cognitive functioning such
as the MMSE is that cognitive impairment is a multifaceted phenomenon and cannot be
accurately determined from the results of a single test (Lezak, 2004).
Another limitation of existing studies on the relationship between dementia and
smoking is that they have used computerized neuropsychological tests (Paul et al., 2006),
which have the advantage of being administered to all participants in exactly the same
way, as well as not requiring trained neuropsychologists for administration. However,
given the absence of a qualified neuropsychologist and that the participants are limited to
pushing keys to register their answers on a computer test, potential cognitive deficits are
determined solely through quantitative methods. Subtle or focal deficits are often missed
without the observations of trained evaluators (Lezak, 2004). In addition, within a group
of elderly participants there are apt to be a number of participants who have little or no
computer experience; their unfamiliarity and potential discomfort with the technology
may affect their test scores. Therefore, the lack of significant differences between current
smokers and never or former smokers in these studies may be due to participants in both
groups lacking familiarity with computers or experiencing computer related anxiety
(Lezak, 2004). Given the limitations of using brief screening instruments and
computerized testing to measure cognitive impairment in smokers, it is important that
future studies use more sensitive and comprehensive testing batteries.
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The majority of studies on the relationship between smoking and dementia were
not able to ascertain the specific cognitive functions affected by cigarette smoking due to
their use of brief screening measures. The investigations that utilized more
comprehensive batteries to determine participant eligibility did not describe the cognitive
deficits associated with smoking. Therefore, a brief search of the literature on the
relationship between smoking and cognitive function was conducted to determine which
areas of cognitive function might be most impaired due to smoking. These studies have
demonstrated an association between current smoking and cognitive decline in four
cognitive domains: executive function, verbal memory, attention, and information
processing speed (Arntzen et al., 2011; Dregan, Stewart, & Gulliford, 2012; Sabia et al.,
2009; Starr et al., 2007). For example, Dregan, Steward, and Gulliford (2012)
investigated the relationship between cardiovascular risk factors, including smoking,
blood pressure, cholesterol levels, and BMI, and cognitive decline in individuals age 50
and older who participated in the English Longitudinal Study of Aging. Cognition was
measured in terms of verbal memory, and executive function was measured in terms of
verbal fluency. Smokers were divided into two groups: never smokers or ex-smokers and
current smokers. The study found that cigarette smoking was the most consistent vascular
risk predictor for cognitive decline across all outcomes. An earlier longitudinal study
(Whitehall II Study; Sabia et al., 2009) examined the association between health
behaviors such as smoking, alcohol consumption, physical activity, and diet, and
cognition in late midlife. The cognitive domains evaluated were again verbal memory
and executive function; however, this study measured abstract reasoning as well as verbal
fluency. The results suggested that the greater the exposure to smoking across midlife,
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the higher the odds that the verbal memory and executive function of participants was
poor. While it is important to determine whether or not an association exists between
smoking and cognitive function, future studies need to utilize multiple measures and
assess the effects of smoking across all cognitive domains in order to gain a greater
understanding of the ways in which cigarette smoke affects the human brain.
In addition to increasing the breadth and sensitivity of measures of cognitive
function, it is important for future studies on the relationship between cigarette smoking
and dementia to control for potential confounding variables. There are several likely
candidates, including cardiovascular disease, type 2 diabetes, substance use, depression,
and anxiety. Cardiovascular disease and diabetes are well-known risk factors for vascular
dementia, Alzheimer’s disease, and cognitive decline (Blom, Emmelot-Vonk, & Koek,
2013; Ng, Turek, & Hakim, 2013; Luchsinger, 2012). Epidemiologic studies have also
shown that cigarette smoking increases the incidence of myocardial infarction and
coronary artery disease (Ambrose & Barua, 2004). Research indicates that type 2 diabetes
is also associated with both cognitive decline and cigarette smoking. Specifically, a
number of studies have reported an association between type 2 diabetes and dementia,
including AD and VaD (Roberts et al., 2013). A longitudinal cohort study of 800 older
participants found that the participants diagnosed with type 2 diabetes had a 65% higher
risk of incidence than those who were not diagnosed with diabetes (Arvanitakis et al.,
2004). Additionally, a large number of studies have found an association between active
cigarette smoking and increased incidence of type 2 diabetes (Willi et al., 2007).
Depression and anxiety are also associated with both cognitive decline and
cigarette smoking (Brady, Haynes, Hartwell, & Killeen, 2013; Holma et al., 2013). In
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older adults, mild depression appears to be associated with subtle weaknesses in visual
memory and nonverbal aspects of general intelligence. However, older adults with
moderate to severe depression demonstrate mild weaknesses in information processing
speed and executive skills (Boone et al., 1995). Depression is not the only disorder
commonly diagnosed in older adults; anxiety is also fairly prevalent in this population
especially individuals with mild cognitive impairment (MCI). An increasing body of
research has shown an association between anxiety and declines in cognitive function in
older adults. This research suggests that older adults with clinical levels of anxiety have
poorer global cognitive function, episodic memory, and aspects of executive function
such as set shifting as compared to non-anxious age-matched controls (Pietrzack et al.,
2012).
According to the literature on the association between nicotine dependence and
psychiatric disorders, approximately 50% of daily smokers have a history of a psychiatric
disorder and they smoke a disproportionately large percentage of the overall number of
cigarettes consumed (Grover, Goodwin, & Zvolensky, 2012). Moreover, individuals who
successfully quit smoking have fewer lifetime depression diagnoses and depressive
symptoms than those who are unsuccessful quitters and current smokers (Jamal, Van der
Does, Cuijpers, & Penninx, 2012). Current smokers with a diagnosis of Major Depressive
Disorder (MDD) have more difficulty quitting than smokers who do not meet the criteria
for MDD and are more likely to be heavy smokers. Furthermore, the severity of
depressive symptoms is associated with the number of days smoked and the number of
cigarettes smoked per day. There also appears to be a bi-directional relationship between
nicotine dependence and anxiety disorders, as the research has found that smoking may
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result in increased anxiety, and individuals experiencing increased levels of anxiety are
more likely to smoke (Moylan, Jacka, Pasco, & Berk, 2013). In fact, nicotine dependent
individuals are more than twice as likely to develop an anxiety disorder than any other
psychiatric disorder. Additionally, the National Epidemiologic Survey on Alcohol and
Related Conditions (NESARC) found that the 12-month prevalence rates of nicotine
dependence were elevated in individuals with panic disorder (Brady, Haynes, Hartwell, &
Killeen, 2013).
Chronic substance use has also been shown to be associated with cognitive
impairment and is highly comorbid with tobacco use. While the research focused on
determining the existence of a relationship between chronic substance abuse and an
increased risk of dementia is not yet conclusive, there have been a number of studies that
demonstrated cognitive impairments in chronic substance users. A recent meta-analysis
suggested that chronic exposure to opiates results in cognitive impairment across a range
of different neuropsychological domains, especially verbal working memory, and
cognitive flexibility in the context of verbal fluency (Baldacchino et al., 2012). For
chronic methamphetamine users, cognitive impairments are most likely seen in
attention/working memory, information processing speed, learning and memory,
executive function, and motor skills (Weber et al., 2012). Repeated ketamine users
demonstrate impairments in spatial working memory, planning, visual recognition, and
semantic memory (Liang et al., 2013).
The research on the association between alcohol consumption and the risk of
dementia or cognitive impairment is more complicated than that for the drugs mentioned
above. As might be expected, heavy chronic alcohol consumption without comorbidities
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and nutritional deficits appears to result in cognitive impairment, specifically involving
memory and executive function (Sinforiani et al., 2011). In contrast, a number of studies
suggest that light-to-moderate alcohol consumption (i.e., no more than two drinks per
day) has a protective effect on cognition similar to the protective effect on the
cardiovascular system (Anstey, Mack, and Cherbuin, 2009; Sinforiani et al. 2011). While
the majority of the cardiovascular protective effects seem to be attributed to the
flavenoids in red wine with antioxidant properties, these protective effects have been
noted for white wine, beer, and distilled spirits as well. According to the literature, the
degree of cognitive impairment has been associated with sex (Mancinelli, Vitali, &
Ceccanti, 2009), duration of abuse, the amount of alcohol consumed, and possibly the age
of abuse onset (Sinforiani et al., 2011).
As was mentioned earlier, tobacco use is highly comorbid with the use of alcohol
and illicit drugs. More than 75% of alcohol and drug dependent individuals early in the
recovery process smoke cigarettes and are often characterized as heavy, highly nicotinedependent smokers (Kalman, Morrisette, & George, 2005). Approximately 80% of
cocaine users and opioid dependent individuals also smoke cigarettes. The Harvard
College Alcohol Study, a survey of over 14,000 randomly chosen college students, found
that students were significantly more likely to smoke cigarettes if they used alcohol and
marijuana (Tullis et al., 2003).
Given that cigarette smoke contains over 4700 neurotoxic compounds; is
associated with increased risk of hypertension and diabetes; and is comorbid with
substance use, depression, and anxiety, all of which are risk factors for dementia, it is
reasonable to hypothesize that cigarette smoking is related to cognitive decline and
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dementia. Therefore, the goal of the current study was to evaluate the effects of cigarette
smoking on cognitive function in four key domains identified in the literature: executive
function, verbal memory, attention, and information processing speed in participants
diagnosed with dementia, after controlling for covariates that have been shown to be
related to both cigarette smoking and dementia in the scientific literature (cardiovascular
disease, type 2 diabetes, substance use, depression, and anxiety). We posited that
cigarette smoking would negatively affect neuropsychological performance in patients
with a dementia diagnosis. In other words, dementia patients who are current smokers
would perform worse on neuropsychological measures of executive function, verbal
memory, attention, and information processing speed than dementia patients who are
long-term ex-smokers or never smokers. In terms of the covariates, the supposition was
that the more cigarettes smoked later in life, the more cognitive impairment would be
noted in domains affected by these factors. Specifically, smoking along with the presence
of cardiovascular disease, depression, or anxiety would be associated with impairments in
executive function and attention/working memory, substance abuse would result
primarily in executive function dysfunction, and type 2 diabetes would be associated with
attention and information processing speed impairments.
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CHAPTER TWO
METHOD

Participants
Participants were patients referred to Harbor UCLA Medical Center for
neuropsychological testing between 1991 and 2011 who were diagnosed with AD, VaD,
mixed dementia (VaD and AD), DLB, FTD, or dementia not otherwise specified (NOS).
The sample consisted of 45.6% males (N = 52) and 54.4% females (N = 62). The ages
ranged from 24 to 85 (M = 58.16, SD = 12.85). The racial/ethnic composition of the
sample was 35.2% African American, 30.6% Caucasian, 14.8% Hispanic, 13.8% Asian,
0.9% Middle Eastern, and 4.6% other. The average level of education was 12.35 years
(SD = 3.04), and ranged from 3 to 18 years. In terms of dementia diagnosis, the sample
comprised 52.1% patients diagnosed with dementia NOS, 24.5% with VaD, 12.3% with
AD, 3.7% DLB, 3.7% with FTD, 2.5% with mixed dementia, and 1.2% dementia due to
substance abuse (Table 1). Average participant cognitive performance is shown in Table
2.
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Table 1
Participant Demographics
Age (years)
Education (years)
Gender
Female
Male
Ethnicity:
African American
Caucasian
Hispanic
Asian
Middle Eastern
Other
Dementia Type:
Dementia NOS
Vascular Dementia
Alzheimer’s Disease
Lewy Body Dementia
Frontal Temporal Dementia
Mixed Dementia
Dementia due to Substance
Abuse

M
58.16
12.35

SD
12.85
3.04

N(%)

62(54.4)
52(45.6)
38(35.2)
33(30.6)
16(14.8)
15(13.9)
1(0.9)
5(4.6)
85(52.1)
40(24.5)
20(12.3)
6(3.7)
6(3.7)
4(2.5)
2(1.2)

Chronic History:
Hypertension
Diabetes
Depression
Anxiety
Substance Use
Tobacco Use

No
38(40.4)
67(72.8)
63(61.8)
93(90.3)
72(72.7)
51(62.6)

Yes
56(59.6)
25(27.2)
39(38.2)
10( 9.7)
27(27.2)
31(37.8)

Table 2
Participant Cognitive Performance
Neuropsychological Measures
WAIS-III Digit Span
WAIS-III Digit Symbol Coding
DKEFS Phonemic Fluency
RAVLT

N
111
80
105
60
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M
6.70
6.84
16.69
1.33

SD
2.66
14.83
10.67
1.79

Measures
Participants were referred for a one-day neuropsychological assessment,
evaluating performance in all cognitive domains: general intellectual functioning,
attention/working memory, language, visuospatial skills, verbal memory, non-verbal
memory, executive functioning, information processing speed, and motor skills. These
assessments typically lasted approximately eight hours. The evaluations involved a
battery of approximately 21 primarily paper and pencil tests, though the composition of
the battery varied somewhat over time. The current study examined participant
performance in the four cognitive domains that research indicates are most affected by
chronic cigarette smoking: executive function, verbal memory, attention/working
memory, and information processing speed. In each domain, one test was selected that
had good internal consistency reliability, had been used in other studies of smoking and
cognitive decline, and had been administered to the majority of participants.

Executive Function
The majority of studies measure executive function using variations of verbal
fluency tasks. Verbal fluency is a cognitive function that facilitates information retrieval
from memory using frontal systems abilities such as selective attention and mental set
shifting. The typical verbal fluency test comprises two tasks, a phonemic fluency task
that involves the generation of as many words as possible that begin with a specified
letter within one minute (e.g., FAS) and a semantic fluency task that requires the
participant to list as many items as s/he can in a specified category (e.g., animals) within
the same time period. For the current study, we chose the Delis-Kaplan Executive
Function System Verbal Fluency Test (DKEFS Verbal Fluency, Delis, Kaplan, &
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Kramer, 2001), with the letters F, A, S for the phonemic fluency subtest, and the category
of animals for the semantic fluency subtest, because the test has good internal consistency
and validity. The internal consistency of the phonemic fluency subtest ranges from .77 to
.90 for ages 20 – 89. While the internal consistency for the semantic fluency subtest is
lower than that of the phonemic fluency subtest (.61 to .76 for the same age range), the
reliability coefficients are comparable to those published for a number of other
commonly used neuropsychological tests, including the Wisconsin Card Sorting Test
(Delis, Kramer, Kaplan, & Holdnack, 2004).

Verbal Memory
The measures used in the literature to evaluate verbal memory take the form of
list learning tasks that involve a list of unrelated words that are presented verbally with
immediate and delayed recall trials (e.g., Rey Auditory Verbal Learning [RAVLT],
California Verbal Learning Test – second edition [CVLT-II]). The RAVLT was utilized
in the current study due to a high internal reliability score (approximately .90; van den
Burg & Kingma, 1999), the measure’s high sensitivity to neurological impairments and
memory deficits in patients with a variety of disorders (Powell et al., 1991), and the fact
that it correlates moderately well with other measures of learning and memory such as the
Wechsler Memory Scale Logical Memory subtest (Johnstone et al., 2000). The RAVLT
requires the examinee to learn a list of 15 words over five trials. Following the five trials,
the examinee is presented with a distractor list and then asked to recall the list of words.
After a 30-minute delay, the examinee is again asked to recall the list of words, and then
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presented with another list of words comprising words from the initial list and words that
were not on the initial list and asked if s/he recognizes each word as being on the first list.

Attention/Working Memory
The current study utilized the Wechsler Adult Intelligence Scale – third edition
(WAIS-III) Digit Span subtest as a measure of simple attention/working memory. Digit
span is composed of two parts: Digit Span forward and Digit Span backwards. In Digit
Span forward, the examinee is presented with an increasingly longer auditory sequence of
digits comprising the numbers zero through nine and asked to repeat the sequence in the
exact order in which it was presented. In contrast, in Digit Span backwards the examinee
is presented a sequence of digits similar to those in the forward portion of the task and
asked to verbally respond with the digit sequence in reverse order. The internal
consistency for WAIS-III Digit Span ranges from .85 to .99, depending on the age group
(for age ranges 30-54, 55-74, & 75-89; Iverson, 2001).

Information Processing Speed
Given that the WAIS-III Digit Symbol Coding subtest was utilized in a number of
investigations into the relationship between smoking and changes in cognitive function
(Arntzen et al., 2011, Starr et al., 2007), it was a logical choice for the current study.
Patients are presented a key that contains digits one through nine and the symbol that
corresponds to each digit. They are given rows of boxes where the top box contains a
digit and the bottom box is empty then asked to fill the bottom boxes with the symbols
corresponding with the digits in the top box as fast as they can. The digit-symbol coding
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score is the number of correct symbols completed in 120 seconds. As with the majority of
neuropsychological measures, the Digit Symbol subtest assesses more than one cognitive
domain. Tests of information processing speed such as Digit Symbol Coding require
intact attention, and cognitive flexibility as well as processing speed to be successfully
completed (Baudouin et al., 2009; Ziegler, 2010). Specifically, Digit Symbol Coding
requires the participant to attend to (attention) and process the stimuli as quickly as
possible (information processing speed), while switching back and forth between
symbols and numbers (cognitive flexibility). According to the WAIS-III technical
manual, the Digit Symbol Coding subtest has an average reliability of .82 (The
Psychological Corporation, 1997).

Tobacco Use
The tobacco data were collected by asking each participant the question “do you
have a history of tobacco use”. The tobacco item required a response of “yes” or “no”.

Covariates
Medical data were collected by asking each participant, “do you have a history of
chronic hypertension,” and “do you have a history of diabetes.” The medical items all
required “yes” or “no” answers. In addition, participants were asked, “do you have a
history of chronic depression,” “do you have a history of chronic anxiety,” “do you have
a history of chronic alcohol use,” “do you have a history of chronic cocaine use,” “do you
have a history of chronic amphetamine use,” and “list any other chronic substances
used.” The definition of “chronic” for the current study was substance use of more than
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one year. The psychiatric/substance use items all required “yes” or “no” answers. For the
present study, participants’ responses on all substance use questions were combined into
one substance use variable, indicating whether they had a chronic history of any type of
substance use (yes or no).

Procedures
Patients were primarily referred for testing by the Psychiatry, Neurology, and
Neurosurgery departments at Harbor-UCLA Medical Center. Additionally, patient
referrals were received from other hospitals and mental health clinics in the surrounding
community. Patients were referred for neuropsychological evaluation in order to
characterize their current cognitive abilities in the context of complaints of memory
decline. The assessment process began with a brief explanation of neuropsychological
assessment and the purpose of the evaluation. Patient confidentiality was discussed and
informed consent was obtained for each participant. A clinical interview, which lasted
approximately one hour, was conducted. Each patient was administered a thorough test
battery that utilized multiple tests to evaluate each cognitive domain (i.e., general
intellectual function, attention/information processing speed, language, visuospatial
ability, verbal and nonverbal memory, and executive function), as well as mood and
motor ability. The tests were all paper and pencil tests administered by a trained clinical
neuropsychologist.
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CHAPTER THREE
RESULTS

Four separate hierarchical multiple linear regression analyses were conducted to
determine if tobacco use is associated with poorer performance on neuropsychological
measures of executive function, attention, information processing speed, and verbal
memory after controlling for cardiovascular disease, diabetes, depression, anxiety, and
substance use. Prior to analysis, the data were evaluated for outliers and multicollinearity,
as well as to determine if the data violated the assumptions of homoscedasticity,
independence of residuals, and normality of residuals. The data violated the normality
assumption. One outlier was removed from the data for each of the four cognitive
measures and an additional outlier was removed from the WAIS-III Digit Span data.
Based on the evaluation of normal probability plots, a logarithmic transformation was
used to normalize the data because they still violated the normality assumption after the
removal of outliers.
To increase statistical power, we simplified the full regression models predicting
WAIS-III Digit Span, WAIS-III Digit Symbol Coding, and the DKEFS phonemic fluency
by only including the independent variables with effect sizes (sr2) greater than .01. The
regression model predicting scores on the RAVLT (Table 8) was not simplified or
interpreted, as the data for the modified model violated the normality assumption for all
of the mathematical transformations attempted. A square root transformation was used
instead of the logarithmic transformation to normalize the data for the simplified models,
based on evaluations of normal probability plots. . The results of independent t-tests
conducted indicated no significant differences in cognitive performance between
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participants with and without a history of hypertension, diabetes, depression, anxiety,
substance use, or tobacco use, with one exception (Table 3). Individuals with diabetes
performed significantly better on WAIS-III Digit Span than individuals without diabetes,
t(89) = -2.26, p < .05. Correlations among the variables used in the regression models
demonstrated positive relationships between hypertension and diabetes, hypertension and
depression, diabetes and attention/working memory performance, executive function
performance and attention/working memory performance, as well as tobacco use and
other substance use (Table 4).
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Table 3
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Group Differences for Cognitive Test Performance
DV
IV
Yes (SD)
No (SD)
t
df
p
Cohen’s d
Digit Span
Hypertension
6.68 (2.12)
6.73 (2.89)
.10
91
.92
-.021
Diabetes
7.56 (2.29)
6.30 (2.39)
-2.26
89
.03
.539
Depression
6.62 (2.086)
6.37 (2.70)
-.50
98
.62
.101
Anxiety
6.90 (2.47)
6.45 (2.50)
-.54
99
.59
-.300
Substance Use
6.26 (2.41)
6.56 (2.55)
.52
95
.60
-.121
Tobacco Hx
6.26 (2.18)
6.39 (2.39)
.25
78
.81
-.057
Digit Symbol
Hypertension
4.44 (3.45)
4.40 (2.45)
-.05
66
.96
.014
Diabetes
4.42 (2.27)
4.57 (3.38)
.18
66
.86
-.049
Depression
3.84 (1.73)
7.14 (14.48)
1.26
72
.21
-.301
Anxiety
4.50 (2.07)
5.88 (11.71)
.33
73
.74
-.125
Substance Use
4.55 (3.94)
6.17 (12.84)
.58
74
.56
-.148
Tobacco Hx
4.12 (2.21)
4.06 (2.70)
-.08
56
.94
.024
FAS
Hypertension
17.23 (10.73)
14.78 (8.79)
-1.13
87
.26
.258
Diabetes
16.29 (10.67)
15.71 (9.73)
-.24
85
.81
.059
Depression
16.35 (10.03)
15.67 (9.78)
-.33
92
.74
.070
Anxiety
21.22 (9.59)
15.49 (9.74)
-1.68
93
.10
.595
Substance Use
15.67 (8.83)
15.75 (10.43)
.03
89
.97
-.008
Tobacco Hx
15.07 (7.71)
15.16 (10.21)
.04
73
.97
-.010
RAVLT
Hypertension
1.60 (2.05)
1.00 (1.41)
-1.11
51
.27
.370
Diabetes
1.80 (1.82)
1.31 (1.87)
-.87
52
.39
.269
Depression
1.18 (1.65)
1.50 (1.90)
.65
56
.52
-.174
Anxiety
1.20 (2.17)
1.37 (1.78)
.20
57
.84
-.096
Substance Use
.94 (1.20)
1.52 (1.98)
1.38
48.02
.17
-.329
Tobacco Hx
1.21 (1.65)
1.60 (2.06)
.68
42
.50
-.211
Note. Bold values of Cohen’s d indicate effect sizes exceeding the recommended minimum effect size of .41

Table 4
Intercorrelations among Covariates and Cognitive Test Performance
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Measure
1. History of Hypertension
2. History of Diabetes
3. History of Depression
4. History of Anxiety
5. History of Tobacco Use
6. History of Substance Use
7. WAIS-III Digit Span
8. WAIS-III Digit Symbol Coding
9. DKEFS Phonemic Fluency
10. Rey Auditory Verbal Learning

1
-.277
.237
-.036
.146
-.093
-.033
.007
.084
.154

2

3

4

5

6

7

8

9

10

-.072
-.012
.033
-.064
.217
-.022
.008
.120

-.148
-.020
-.116
.072
-.147
.094
-.086

-.128
.055
.047
-.039
.145
-.027

-.393
-.046
.011
.016
-.104

--.064
-.067
.025
-.148

--.202
.512
-.174

--.054
.245

-.162

--

Note. Bold correlation values are significant at p < .05.

The author hypothesized that within a sample of dementia patients those who
were current smokers would perform worse on select neuropsychological measures of
executive function, verbal memory, attention, and information processing speed than
those who are nonsmokers. Hierarchical regressions predicting cognitive performance
from tobacco use history after controlling for history of hypertension, diabetes,
depression, anxiety, and substance use were conducted to test this prediction. Results of
the full, originally hypothesized regression models can be found in Tables 5 – 8, and
results of the simplified regression models can be found in Tables 9 – 11. Contrary to the
hypothesis, smoking did not significantly affect performance on measures of executive
function, verbal memory, attention, or information processing speed in patients diagnosed
with dementia, p > .05. In addition, none of the covariates significantly predicted
cognitive performance in any domain, in either the full or simplified regression models, p
> .05.
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Table 5
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Results of a Multiple Linear Regression Analysis Predicting WAIS-III Digit Span Performance
(Full Model, Logarithmic Transformation)
95% Cl
Predictor
Step
B
SE
β
[Lower, Upper]
p
sr2
Variable
1
Hypertension
-.015
.041
-.047
[-.097, .067]
.723
.00194
Diabetes
.087
.046
.245
[-.004, .179]
.060
.05476
Depression
.047
.042
.143
[-.036, .131]
.260
.01932
Anxiety
.008
.067
.014
[-.127, .134]
.908
.00020
Substance Use
-.014
.044
-.040
[-.102, .073]
.746
.00160
2
Hypertension
-.024
.042
-.075
[-.108, .060]
.575
.00476
Diabetes
.087
.046
.243
[-.004, .178]
.062
.05382
Depression
.051
.042
.155
[-.033, .135]
.227
.02220
Anxiety
-.007
.069
-.013
[-.145, .131]
.919
.00014
Substance Use
-.030
.046
-.083
[-.122, .063]
.523
.00608
Tobacco History
.045
.043
.139
[-.042, .131]
.307
.01588

Table 6
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Results of a Multiple Linear Regression Analysis Predicting WAIS-III Digit
Performance (Full Model, Logarithmic Transformation)
95% Cl
Predictor
Step
B
SE
β
[Lower, Upper]
Variable
1
Hypertension
.011
.086
.021
[-.163, .185]
Diabetes
-.084
.093
-.142
[-.272, .105]
Depression
.003
.081
.006
[-.161, .167]
Anxiety
-.007
.120
-.009
[-.248, .234]
Substance Use
-.086
.086
-.148
[-.259, .088]
2
Hypertension
.008
.088
.014
[-.170, .185]
Diabetes
-.088
.095
-.149
[-.280, .105]
Depression
.009
.084
.016
[-.161, .178]
Anxiety
-.016
.124
-.020
[-.266, .235]
Substance Use
-.094
.091
-.163
[-.278, .090]
Tobacco History
.026
.087
.049
[-.150, .201]

Symbol Coding

p

sr2

.897
.376
.969
.953
.325
.931
.363
.920
.900
.309
.768

.00036
.01742
.00004
.00008
.02161
.00017
.01877
.00023
.00036
.02371
.00194

Table 7
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Results of a Multiple Linear Regression Analysis Predicting DKEFS Phonemic
Performance (Full Model, Logarithmic Transformation)
95% Cl
Predictor
Step
B
SE
β
[Lower, Upper]
p
Variable
1
Hypertension
-.011
.133
-.011
[-.278, .256]
.934
Diabetes
.030
.149
.027
[-.268, .327]
.842
Depression
.185
.134
.183
[-.085, .454]
.175
Anxiety
.133
.232
.074
[-.332, .597]
.570
Substance Use
.071
.143
.065
[-.215, .358]
.620
2
Hypertension
-.032
.135
-.033
[-.302, .238]
.816
Diabetes
.015
.149
.014
[-.284, .314]
.919
Depression
.195
.135
.194
[-.075, .466]
.153
Anxiety
.070
.241
.039
[-.413, .552]
.773
Substance Use
.011
.155
.010
[-.300, .323]
.942
Tobacco History
.145
.147
.146
[-.149, .439]
.328

Fluency

sr2
.00012
.00068
.03098
.00533
.00410
.00090
.00017
.03460
.00137
.00008
.01588

Table 8

31

Results of a Multiple Linear Regression Analysis Predicting RAVLT Long Delay Performance (Full
Model, Logarithmic Transformation)
95% Cl
Predictor
Step
B
SE
β
[Lower, Upper]
p
sr2
Variable
1
Hypertension
.139
.277
.091
[-.432, .701]
.619
.00689
Diabetes
.251
.303
.144
[-.365, .867]
.414
.01877
Depression
-.145
.271
-.093
[-.695, .406]
.597
.00792
Anxiety
-.178
.462
-.064
[-1.116, .761]
.703
.00410
Substance Use
-.214
.259
-.138
[-.741, .313]
.414
.01877
2
Hypertension
.154
.287
.100
[-.431, .739]
.597
.00810
Diabetes
.250
.308
.143
[-.376, .876]
.422
.01877
Depression
-.150
.276
-.096
[-.710, .411]
.591
.00828
Anxiety
-.183
.469
-.066
[-1.137, .771]
.699
.00436
Substance Use
-.185
.291
-.119
[-.778, .408]
.530
.01145
Tobacco History
-.067
.283
-.045
[-.643, .510]
.815
.00160

Table 9
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Results of a Multiple Linear Regression Analysis Predicting WAIS-III Digit Span Performance
(Simplified Model, Square Root Transformation)
95% Cl
Predictor
Step
B
SE
β
[Lower, Upper]
p
sr2
Variable
1
Diabetes
203
.113
.214
[-.021, .428]
.076 .04537
Depression
.048
.106
.053
[-.164, .259]
.653 .00281
2
Diabetes
.201
.113
.211
[-.025, .427]
.080 .04452
Depression
.048
.106
.054
[-.164, .260]
.652 .00292
Tobacco History
.080
.102
.093
[-.124, .283]
.437 .00865

Table 10
Results of a Multiple Linear Regression Analysis Predicting WAIS-III Digit Symbol Coding
Performance (Simplified Model, Square Root Transformation)
95% Cl
Step
Predictor Variable
B
SE
β
[Lower, Upper]
p
sr2
1
Diabetes
-.061
.176
-.043
[-.411, .290]
.731
.00185
Substance Use
-.044
.173
-.032
[-.389, .301]
.801
.00102

Table 11
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Results of a Multiple Linear Regression Analysis Predicting DKEFS Phonemic
(Simplified Model, Square Root Transformation)
95% Cl
Predictor
Step
B
SE
β
[Lower, Upper]
Variable
1
Depression
.306
.323
.111
[-.338, .950]
2
Depression
.308
.324
.112
[-.339, .954]
Tobacco History
.232
.324
.084
[-.414, .878]

Fluency Performance

p

sr2

.347
.346
.477

.01232
.01254
.00706

CHAPTER FOUR
DISCUSSION

Results of regression models predicting performance in select cognitive domains
did not confirm the primary hypothesis that participants diagnosed with dementia who are
current smokers would perform worse on measures of executive function,
attention/working memory, verbal memory, and information processing speed than those
who are current nonsmokers. Although the sample sizes for the RAVLT and WAIS-III
Digit Symbol Coding tests were small, the null results are unlikely to be due to low
statistical power because the effect sizes for the majority of the independent variables in
the regression models were less than .001. This means that most of the independent
variables account for less than .1% of the variance in the performance on the
neuropsychological measures investigated, which would not be clinically significant even
if it were statistically significant. Furthermore, simplifying the models to increase
statistical power did not yield any significant results and the effect sizes were still very
small (less than .01).
The only potential statistical issue encountered in the current study was the odd
finding that participants with diabetes performed significantly better on a measure of
simple auditory attention/working memory than participants without diabetes. The
literature does not support this finding. In fact, studies typically show that individuals
with diabetes perform more poorly on tests of cognitive function (e.g., Mehrabian et al.
2011). This questionable outcome may be due to Type 1 error as a result of the large
number of t-tests (24) performed on the data. If we apply the Bonferroni correction for
Type I error to the number of t-tests that were conducted (corrected alpha = .05/24), then
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the cutoff for significance becomes .002, which renders the effect of diabetes on digit
span performance no longer significant.
Given that the null results are most likely not due to statistical problems, one
explanation for the current findings may simply be that cigarette smoking does not affect
cognitive functioning. However, there are enough studies that have suggested a
relationship between cigarette smoking and cognitive decline that the null findings of the
current study are more likely to be attributable to methodological limitations. One
methodological limitation was our inability to separate the participants into two groups,
long-term ex-smokers and never smokers, and current smokers and recent ex-smokers,
because the data were archival. As such, the data did not include the information
necessary to split smokers into these groups. A number of studies have found that exsmokers either have similar declines in cognition or slower declines than never smokers
due to the ambiguous definition of former smokers (Anstey et al., 2007; Peters et al.,
2008; Sabia et al., 2012). The studies that differentiated between the two levels of exsmokers found that long-term former smokers exhibited similar risk of cognitive
impairment as never smokers (Galanis et al., 1997; Sabia et al., 2012). Almeida et al.
(2011) found that the cognitive scores of chronic smokers (i.e., smoked a minimum of
five cigarettes per day for a continuous period of 12 months or more throughout their
lifetime) who quit smoking for a minimum of 18 months were comparable to those of
never smokers. In fact, it is possible that long-term former smokers’ risk may be reduced
to the level of never smokers’ risk, although more research is needed to confirm this.
The tobacco literature indicates that many of the body’s systems damaged by
cigarette smoking return to the condition of a nonsmoker when the smoker has abstained
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from smoking for a long enough duration (e.g., risk of coronary heart disease is the same
as for nonsmokers after 15 years of abstinence; Abrams et al., 2003). Given that the heart
and lungs heal, and a number of the studies of the relationship between smoking and
cognition found no differences between the cognition of never smokers and long-term exsmokers (Galanis et al., 1997; Sabia et al., 2012), it is possible that the brain heals as well
or that a reduction in cardiovascular risk translates into a reduction in the risk for
dementia. Therefore, future studies should categorize ex-smokers as either recent or longterm ex-smokers to account for the body’s ability to heal itself. Similar temporal
arguments may also apply to several of the other independent variables. Factors that may
cause neurological damage, such as hypertension, diabetes, or substance use, likely cause
cognitive deficits to a degree that depends on the severity, duration, and recency of the
insult.
Another issue that may have affected the primary outcome of the study was that
smoking may be more likely to be associated with certain types of dementia than others,
but we had to combine patients with different dementia diagnoses into one large group
because there were not enough patients diagnosed with the different types of dementia to
examine them separately. The most common types of dementias stem from different
changes in brain pathology such as the amyloid beta plaques and tau tangles that
characterize AD (Hashimoto, Rockenstein, Crews, & Masliah, 2003); the abnormal
accumulation of α-synuclein in neuronal cell bodies, axons, and synapses found in DLB
(Hashimoto, Rockenstein, Crews, & Masliah, 2003); and the hemorrhagic, ischemic, or
hypoperfusive lesions that are the hallmark of VaD (Roman & Benavente, 2003).
Therefore, it is not unreasonable to posit that smoking may affect each of these disease
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processes differently. In fact, a study by Reitz et al. (2007) found an association between
current smoking and increased risk of AD but not of VaD, which suggests that the
relationship between smoking and risk of a neurodegenerative disease may not be the
same for the different types of dementias. Future work needs to be conducted to
determine if there are differences in the association between smoking and increased risk
of different types of dementia, as well as whether or not smoking exacerbates or changes
the symptomatology of the different dementias.
The results of Rusanen et al.’s investigation (2011) not only indicated that the
relationship between current smoking and increased risk of dementia was stronger for
VaD than AD, they also suggested that the association was dose dependent. These
associations were only seen in participants who currently smoked more than two packs
per day. The increased risk of VaD in participants who currently smoked one to two
packs per day was trending toward statistical significance, while the risk of AD in
participants who currently smoked one to two packs per day was not significant. Neither
the increased risk of VaD or AD was significant for participants who currently smoked
less than one pack per day. In the current study’s sample, the majority of participants who
currently smoked reported that they smoked one pack of cigarettes or less per day (M =
.41, SD = .54). If the outcome is dose dependent, as suggested by Rusanen et al. (2011),
then participants in the current study may not have smoked enough cigarettes to influence
the development of dementia or to differentially affect their cognitive performance (i.e.,
more than 2 packs per day).
In addition, the smoking history data were collected by self-report, which is
potentially problematic given this sample. According to the test scores for several verbal
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memory measures, the majority of the participants are likely to be amnestic, and therefore
the accuracy of their reported cigarette consumption may be questionable. Future work
should check the accuracy of the information collected from participants using
biochemical verification of smoking status (to the extent possible) and brief interviews
with non-amnestic friends or family members.
The complex nature of the sample analyzed for the current study gave us the
opportunity to conduct this investigation using a diverse sample that is more reflective of
real life, rather than one that is primarily Caucasian and homogenous in terms of
diagnosis. Unfortunately, the complexity may have also obscured any clear-cut
relationships among the variables due to decreased internal validity. There were many
uncontrolled factors that may have influenced cognitive performance, such as varying
levels of SES, various cultural backgrounds, or histories of homelessness, domestic
violence, or other trauma. For example, several studies on the effects of homelessness on
neuropsychological functioning have found deficits in information processing speed
(Seidman et al., 1997) and executive functioning (Gonzalez, Dieter, Natale, & Tanner).
Another factor that may explain the null results of the current study was the use of
a cross-sectional design. Unlike a prospective study, the participants in a cross-sectional
study are only assessed at one point in time, and thus there is only one opportunity to
observe an effect. Utilizing a prospective study design would have enabled us to observe
changes in cognitive performance over time, particularly in relation to changes in
smoking habits. Future work should recruit smokers and non-smokers in early or middle
adulthood, and assess their smoking behavior and cognitive performance over time.
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In the case of the current study, it is probable that participants were at different
points in the neurodegenerative disease process, which may have affected study
outcomes. For example, we may be more likely to see an association between smoking
and poorer performance on select neuropsychological tests early in the disease process,
because later on individuals’ cognition is more likely to be severely impaired across
multiple domains. Thus, future studies should include participants who are identified as
early as possible in the disease process. However, the only way to determine that
participants are at an optimal point in their disease for detecting differences is if they
undergo neuropsychological testing, which would make recruiting participants difficult.
Although the use of a prospective design would have been more
methodologically robust, we would still have encountered the problem that statistical
modeling of the effect of smoking on AD patients is complicated by the existence of
competing risk due to mortality (Chang, Zhao, Lee, & Ganguli, 2012). Given that
smokers tend to die at an earlier age than non-smokers, the older smokers in our sample
are likely to be the healthiest smokers for a given age group, which suggests that we may
be comparing cognitive performance between nonsmokers and the healthiest smokers.
The differences in the cognitive skills between these groups may be much smaller than in
a comparison with unhealthier smokers who are either deceased or have more urgent
health issues to deal with than cognitive decline. Similar arguments apply to the other
variables that could affect mortality, including hypertension, diabetes, substance use, and
even depression. For example, individuals with severe hypertension or uncontrolled
hypertension may not live long enough to develop dementia or experience a decline in
cognition, and therefore samples of older participants with hypertension may comprise
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healthier hypertensive individuals that are more likely to have milder cognitive deficits
than individuals with more severe hypertension who survived to the same age.
A more likely reason for the null results is that the cognition of participants at the
time of testing was so impaired that the predicted small effect of smoking or any of the
other independent variables on cognitive performance was obscured due to a ceiling
effect. Examination of the scores for the measure of verbal memory (RAVLT) showed
that the average participant was able to recall only one word and more than half of the
participants could not recall any of the words, which suggests that the participants were
predominantly amnestic and fairly advanced in the disease process. Further evidence of
the level of participant memory impairment is that the average participant scored in the
impaired range for another test of verbal memory with the same duration of delay, WMSIII Logical Memory II.
Possible directions for future research include better separation of subjects into
groups based on the amount and recency of their tobacco consumption, and use of
techniques other than self-report to confirm smoking history and status. More research
needs to be conducted that focuses on potential associations between cigarette smoking
and the risk of different types of dementias, given the differences in pathology and
mechanisms of neurodegeneration. Most importantly, future investigations should use a
prospective design to study changes in cognition over time. Utilizing a prospective design
that begins in early or middle adulthood and involves administering repeated
neuropsychological batteries over time may help resolve the problems caused by recall
bias, differential mortality, and evaluation of participants at different stages in the
neurodegenerative process.
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